Expand IFRX Menu
IFRX MENU

IFRX Latest Press Releases

-- March 13, 2026 --

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Globe Newswire 5:00 PM

-- March 12, 2026 --

InflaRx to Report Full Year 2025 Results on March 19, 2026 Globe Newswire 7:30 AM

-- February 26, 2026 --

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference Globe Newswire 7:30 AM

-- January 29, 2026 --

InflaRx Announces Participation in February Investor Conferences Globe Newswire 7:30 AM

-- January 8, 2026 --

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation Globe Newswire 8:00 AM
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation Globe Newswire 8:00 AM

-- December 30, 2025 --

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum Globe Newswire 7:30 AM

-- December 11, 2025 --

InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904 Globe Newswire 7:30 AM

-- November 10, 2025 --

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) Globe Newswire 7:30 AM

-- November 7, 2025 --

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria Globe Newswire 4:05 PM

-- October 21, 2025 --

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference Globe Newswire 7:20 AM
Market Data Delayed 15 Minutes